Daiichi Sankyo Company has launched Pralia subcutaneous injection 60mg syringe (generic name denosumab) for the treatment of osteoporosis, following its manufacturing and marketing approval in Japan.
Designed to specifically inhibit an essential mediator for bone resorption RANKL, the human monoclonal antibody is indicated for injecting subcutaneously every six months to treat osteoporosis.
Pralia demonstrated its efficacy in reducing risk of vertebral fracture in a clinical study conducted on osteoporosis patients in Japan.
In 2007, Daiichi Sankyo acquired license rights to denosumab from Amgen to develop and market the antibody in Japan.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/daiichi-sankyo-launches-pralia-subcutaneous-injection-60mg-syringe-120613
